Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

April 30, 2020

Study Completion Date

October 15, 2020

Conditions
Prostate Cancer Metastatic
Interventions
DRUG

Veru-944

Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT

DRUG

Placebo

Placebo

Trial Locations (24)

11003

Advance Urology, Elmont

11530

AccuMed Research, Garden City

12601

Premier Medical Group of the Hudson Valley, Poughkeepsie

13210

Associated Medical Professionals, Syracuse

19004

Urologic Consultants, Bala-Cynwyd

21204

Chesapeake Urology, Towson

23462

Urology of Virginia, Virginia Beach

33144

Medical Research Center, Miami

33166

Universal Axon Clinical Research, Doral

44130

Clinical Research Solutions, Middleburg Heights

47130

First Urology, Jeffersonville

71101

Regional Urology LLC, Shreveport

75230

Mary Crowley Cancer Research, Dallas

75231

Urology Clinics of North Texas, Dallas

77091

Houston Urology Partners, Houston

78229

Urology San Antonio, San Antonio

80211

The Urology Center of Colorado, Denver

80401

Foothills Urology, Golden

83814

North Idaho Urology, Coeur d'Alene

85308

Gen1 Research, Glendale

90048

Tower Urology, Los Angeles

92404

Urology of San Bernardino, San Bernardino

08724

Coastal Urology, Brick

08837

Premier Urology Group, Edison

All Listed Sponsors
lead

Veru Inc.

INDUSTRY

NCT03646162 - Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter